Drug Approvals Analysis

Lilly buys 4E in non-opioid pain push: what investors should watch

FDA · moderate to severe acute pain · 6 min

FDA MRD guidance in multiple myeloma: what BD teams should track

FDA · multiple myeloma · 6 min

Medicare GLP-1 coverage 2026: Bridge program starts July 1

GLP-1 · 7 min

AbbVie Cerevel acquisition closes in $8.7B neuroscience deal

immunology · 6 min

Vabysmo gains EU approval for retinal vein occlusion: what changes next

FDA · retinal vein occlusion · 6 min

Novartis remibrutinib wins Phase 3 in CSU: what it means

chronic spontaneous urticaria · 9 min

EMA backs datopotamab deruxtecan, but lung cancer access remains unclear

EMA · lung cancer · 9 min

FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain

FDA · moderate-to-severe acute pain · 7 min

Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria

chronic spontaneous urticaria · 8 min

EMA backs datopotamab deruxtecan for advanced lung cancer

EMA · lung cancer · 10 min

AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands

U.S. Federal Trade Commission · immunology · 5 min

Lenacapavir posts 100% HIV prevention in PURPOSE 1

FDA · HIV · 8 min